REG - Oxford Biomedica PLC - Notice of Interim Results

Oxford BioMedicaAnnouncement

27/08/2020 07:00

For best results when printing this announcement, please click on link below:
http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20200827:nRSa2575Xa

RNS Number : 2575X  Oxford Biomedica PLC  27 August 2020

 

 

Notice of Interim Results

 

 

 

Oxford, UK - 27 August, 2020: Oxford Biomedica plc (LSE:OXB) ("Oxford
Biomedica" or "the Group"), a leading gene and cell therapy group, will be
announcing its interim results for the six months ended 30 June 2020 on
Thursday 17 September 2020.

 

A virtual briefing and Q&A session for analysts will be held at 13.00 BST
/ 08.00 EST on the day of results, and the presentation and webcast details
will be made available on the Group's website at www.oxb.com
(http://www.oxb.com) . A replay webcast will be made available shortly
afterwards.

 

 

-Ends-

 Enquiries:

 Oxford Biomedica plc

 John Dawson, Chief Executive Officer                      T: +44 (0)1865 783 000

 Stuart Paynter, Chief Financial Officer                   T: +44 (0)1865 783 000

 Catherine Isted, Head of Corporate Development & IR       T: +44 (0)1865 954 161 / E: ir@oxb.com

 Consilium Strategic Communications

 Mary-Jane Elliott / Matthew Neal                          T: +44 (0)20 3709 5700 /

 

 

 

 

About Oxford Biomedica

 

Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell
therapy group focused on developing life changing treatments for serious
diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a
sector leading lentiviral vector delivery platform (LentiVector®), which the
Group leverages to develop in vivo and ex vivo products both in-house and with
partners. The Group has created a valuable proprietary portfolio of gene and
cell therapy product candidates in the areas of oncology, ophthalmology, CNS
disorders, liver diseases and respiratory disease. The Group has also entered
into a number of partnerships, including with Novartis, Bristol Myers Squibb,
Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Santen, Boehringer
Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial
Innovations, through which it has long-term economic interests in other
potential gene and cell therapy products. Additionally the group has signed a
Clinical and Commercial Supply Agreement with AstraZeneca for manufacture of
the adeno based COVID-19 vaccine candidate, AZD1222. Oxford Biomedica is based
across several locations in Oxfordshire, UK and employs more than 550 people.
Further information is available at  www.oxb.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORQQLFLBVLEBBQ